Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Vera FrisonAnnunziata Lapolla

Abstract

Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. This was a multicenter retrospective observational study. Liraglutide was used under routine clinical practice conditions. Changes from baseline to 60 months in HbA1c, fasting plasma glucose (FPG), body weight, blood pressure, and lipid profile were assessed. United Kingdom Prospective Diabetes Study (UKPDS) scores were calculated at baseline and after 60 months to assess changes in the estimated 5- and 10-year risk for fatal and nonfatal coronary heart disease (CHD) and fatal and nonfatal stroke. Overall, 103 patients (age 59.0 ± 7.9 years, diabetes duration 10.4 ± 6.8 years) were involved in the study. After 60 months, HbA1c levels were reduced by - 1.0 ± 1.2%, FPG levels by - 24.5 ± 43.4 mg/dl, body weight by - 5.3 ± 6.4 kg, systolic blood pressure by - 6.5 ± 18.5 mmHg, diastolic blood pressure by - 3.6 ± 11.8 mmHg, and total cholesterol by - 16.9 ± 37.4 mg/dl. The proportion of patients achieving HbA1c levels  of < 7% increased from 12.7% to 39.8% (p = 0.02). Based on the UKPDS scores, statistically significant reductions in t...Continue Reading

References

Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Feb 1, 2012·Nature Reviews. Cardiology·Jacob SivertsenTina Vilsbøll
Jun 8, 2012·Experimental Diabetes Research·Matteo MonamiEdoardo Mannucci
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 28, 2016·Cell Metabolism·Daniel J Drucker
Jun 29, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Amrita OstawalWeiwei Xu
Oct 28, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Maja Cigrovski BerkovicTomislav Bozek

❮ Previous
Next ❯

Citations

Sep 22, 2020·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Mark P MaskeryHedley Ca Emsley
Jan 2, 2020·International Journal of Environmental Research and Public Health·Maria MirabelliAntonio Brunetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.